Arcturus Therapeutics ARCT 深 沪
已收盘 05-08 16:00:00 美东时间
9.22
+0.320
+3.60%
华盛通- 最 高9.58
- 今 开8.22
- 成交量 93.38万股
- 最 低 7.86
- 昨 收 8.90
- 总市值 2.62亿
- 52周最高 24.17
- 市盈率 静 --
- 换手率 3.29%
- 52周最低 5.85
- 委 比 47.00%
- 总股本 2842.31万
- 历史最高 129.71
- 量 比 2.43
- 振 幅 19.33%
- 历史最低 4.11
- 每 手 1
- 风险率 4.63%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Arcturus Therapeutics Signals Progress Amid Revenue Slip
Arcturus Therapeutics (($ARCT)) has held its Q1 earnings call. Read on for the ...
05-09 09:17
Arcturus Therapeutics Holdings shares are trading lower after the company reported worse-than-expected Q1 sales results.
Arcturus Therapeutics Holdings shares are trading lower after the company repor...
05-08 05:08
Cathie Wood's ARK boosts Palantir, Tesla, Roninhood bets; cuts semiconductor exposure
Cathie Wood’s ARK Invest funds executed a broad rotation across technology, healthcare, and industrial names during the last week while markets remained volatile over broader geopolitical tensions bet...
04-13 19:02
Cathie Wood's Ark Invest in broad sell-off; trims AI, crypto, internet names
Cathie Wood’s ARK Invest actively rotated out of large-cap technology, crypto-linked equities, and consumer internet names during the last week, while only selectively adding a few names. The firm’s...
03-31 18:35
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22
B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $22.
03-18 18:45
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Piper Sandler Maintains Overweight on Arcturus Therapeutics, Lowers Price Target to $25
Piper Sandler analyst Yasmeen Rahimi maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Overweight and lowers the price target from $72 to $25.
03-04 21:47
